Sticking to front-end value

Since it was founded in 2004, Codon Devices Inc. has used its BioFAB technology to provide synthetic gene constructs on a fee-for-service basis to customers in the pharmaceutical, agbiotech and industrial biotech markets. Last week, the synthetic biology company entered its first deal for biopharma product development with Merrimack Pharmaceuticals Inc.

Codon will use its BioLOGIC protein optimization platform,which encompasses and builds upon BioFAB, to design, synthesize and optimize full-length, functional therapeutic proteins against targets identified by Merrimack, according to Merrimack's specifications. ...